Over the counter statins — a good idea?

Haffner SM , Lehto S. , Ronnemaa T. et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. New Engl J Med 1998;339:229-34.

Long-term intervention with pravastatin in ischaemic disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New Engl J Med 1998;339:1349-57.

Sacks FM , Pfeffer MA , Moye LA et al. For the cholesterol and recurrent events trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med 1996;335:1001-09.

Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 444 patients with coronary heart disease: the Scandinavian Survival Study (4S). Lancet 1994;344:1383-9.

Shepherd J. , Ford I. , Cobbe SM et al. for the West of Scotland Coronary Prevention Study Group (WOSCOP). Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. New Engl J Med 1995;333:1301-07.

Downs JR , Clearfield M. , Weis S. et al. for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22.

Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.

Jones P. , Kafonek S. , Laurora I. et al. Comparative dose efficacy of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolaemia (the CURVES study). Am J Cardiol 1998;81: 582-7.

Royal Pharmaceutical Society. Practice Guidance: OTC Simvastatin 10 mg. Pharm J 2004;273:169-70.

Ellis JJ , Erickson SR , Stevenson JG et al. Sub-optimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med 2004;19:638-45.